Millennium: The Takeda Oncology Company Release: Journal of Clinical Oncology Publishes Data on Overall Survival Benefit of VELCADE(R) (Bortezomib) for Injection in Patients with Previously Untreated Multiple Myeloma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today announced the publication of results from the 682-patient, randomized, international Phase III VISTA1 trial in the Journal of Clinical Oncology (JCO). The results continue to show an extension in the length of life for patients taking VELCADE, melphalan and prednisone (VcMP) in the front-line setting compared to MP alone.